

Listing of Claims**In the claims:**

1 – 12. Canceled

13. (Currently amended) A method of treating ~~preventing the development of an immune response to a self antigen in~~ a subject at risk for developing an immune response to a self antigen comprising, administering an enhancing agent which activates NK-T or CD25+ cells to the subject, wherein the enhancing agent is a bacterial cell lysate or is derived from a multicellular parasite and comprises molecules presented in the context of CD1 molecules.

14. Canceled

15. Canceled

16. (Currently amended) A method of treating ~~ameliorating the symptoms of an ongoing immune response to a self antigen in~~ a subject suffering from an ongoing immune response to a self antigen comprising administering an enhancing agent which activates NK-T or CD25+ cells to the subject, wherein the enhancing agent is a bacterial cell lysate or is derived from a multicellular parasite and comprises molecules presented in the context of CD1 molecules.

17. (Previously presented) The method of claim 13 or 16, wherein the enhancing agent is a bacterial cell lysate.

18. (Currently amended) The method of claim 13 or 16 ~~17~~, wherein the enhancing agent is administered orally.

19. Canceled

20. (Previously presented) The method of claim 17, wherein the bacterial cell lysate is derived from a bacterium belonging to the genus *Mycobacteria*.

21-24 Canceled

25-26 Canceled

27-32 Canceled

33. (Previously presented) The method of claim 17, wherein the enhancing agent is a lysate of bacterial cells of a genus selected from the group consisting of: *Lactobacillus*, *Bordatella*, *Corynebacterium*, *Streptococcus*, and *Hemophilus*.

34. (Previously presented) The method of claim 17, wherein the enhancing agent comprises lipids and glycolipids.

35. Canceled.

36. (Currently amended) The method of claim 1317, wherein the subject is determined to be at risk for developing an autoimmune response to a self antigen by ~~further comprising~~ determining the number or level of indicator T cells or the activity of indicator T cells ~~prior to administration of the enhancing agent.~~

37. (Currently Amended) The method of claim 13 or 1617, further comprising determining the number or level of indicator T cells or the activity of indicator T cells subsequent to administration of the enhancing agent.

38. (Previously presented) The method of claim 37, wherein the number or level of indicator T cells is measured using an antibody that recognizes T and NK-T cell surface markers selected from a group consisting of: i) an antibody that recognizes CD3 in combination with an antibody that recognizes at least one of CD69, CD94, and CD161; ii) an antibody that recognizes a TCR variable gene expressed region preferentially expressed by NK-T cells in combination with an antibody that recognizes at least one of CD69, CD94, and CD161; and iii) an antibody that recognizes a TCR variable gene expressed region preferentially expressed by NK-T cells in combination with an antibody that recognizes CD3 and an antibody that recognizes at least one of CD69, CD94, and CD161.

39. (Previously presented) The method of claim 38, wherein the antibody that recognizes a TCR variable region preferentially expressed by NK-T cells recognizes V α 24 and V β 11 and J α Q.

40. (Previously presented) The method of claim 37, wherein the number or level of indicator cells is measured by detecting CD4+/CD25+ T cells that are CD122 or CD132 negative.

41. (Currently amended) The method of claim 37, wherein the activity of indicator cells is measured by determining level of cytokines produced by the indicator cells ~~is determined~~.

42. (Previously presented) The method of claim 17, further comprising administering an immunogen.

43. (Previously presented) The method of claim 17, further comprising administering a TH2 cytokine.

44. (Previously presented) The method of claim 17, wherein the autoimmune response to a self antigen results in diabetes.